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Abstract
A low-grade pro-inflammatory state is at the pathogenic core of obesity and type 2 diabetes. We tested the hypothesis that
the plant terpenoid compound ginsenoside Rb1 (Rb1), known to exert anti-inflammatory effects, would ameliorate obesity,
obesity-associated inflammation and glucose intolerance in the high-fat diet-induced obese mouse model. Furthermore, we
examined the effect of Rb1 treatment on central leptin sensitivity and the leptin signaling pathway in the hypothalamus. We
found that intraperitoneal injections of Rb1 (14 mg/kg, daily) for 21 days significantly reduced body weight gain, fat mass
accumulation, and improved glucose tolerance in obese mice on a HF diet compared to vehicle treatment. Importantly, Rb1
treatment also reduced levels of pro-inflammatory cytokines (TNF-a, IL-6 and/or IL-1b) and NF-kB pathway molecules (p-IKK
and p-IkBa) in adipose tissue and liver. In the hypothalamus, Rb1 treatment decreased the expression of inflammatory
markers (IL-6, IL-1b and p-IKK) and negative regulators of leptin signaling (SOCS3 and PTP1B). Furthermore, Rb1 treatment
also restored the anorexic effect of leptin in high-fat fed mice as well as leptin pSTAT3 signaling in the hypothalamus.
Ginsenoside Rb1 has potential for use as an anti-obesity therapeutic agent that modulates obesity-induced inflammation
and improves central leptin sensitivity in HF diet-induced obesity.
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Introduction
Obesity has reached epidemic proportions and is an important
risk factor for the development of type 2 diabetes, cardiovascular
disease and cancer. It is generally accepted that a low-grade pro-
inflammatory state is at the pathogenic core of obesity and type 2
diabetes [1,2]. This inflammatory response includes elevated levels
of pro-inflammatory cytokines, such as tumor necrosis factor alpha
(TNF-a), interleukin 1 beta (IL-1b) and interleukin 6 (IL-6), and
activation of the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB) signaling pathway, including inhibitor
kappa B alpha (IkBa) and IkB kinase (IKK) [3,4]. The activation
of pro-inflammatory cytokines and NF-kB signaling pathway
mediate the transcription of the suppressor of cytokine signaling 3
(SOCS3) and protein-tyrosine phosphatase 1B (PTP1B), negative
regulators of insulin and leptin signaling, which induce insulin and
leptin resistance in peripheral tissues and the central nervous
system [5,6,7]. Obesity associated inflammation in white adipose
tissue and the liver leads to glucose intolerance, insulin resistance
and metabolic dysfunction [2,8,9]. Over-nutrition and obesity also
leads to hypothalamic inflammation and stimulation of local pro-
inflammatory NF-kB signaling, resulting in the dysfunction of
hypothalamic neurons [4,5]. Furthermore, recent studies have
shown that induction of inflammation in the hypothalamus results
in experimental obesity, resistance to the anorexigenic hormone
leptin, peripheral insulin resistance and defective regulation of
food intake and energy expenditure [10,11,12].
Targeted deletion of certain genes important for mediating
inflammatory responses protect against the development of
hyperglycemia, insulin resistance and obesity in obese mouse
models. Disruption of the gene encoding IKK and the innate
immune system receptor Toll-like receptor (TLR)-4 in mice
confers protection from insulin and leptin resistance, and obesity
in mouse models [5,13]. Also, inhibition of NF-kB signaling using
high-dose salicylates confers protection from obesity-induced
inflammation and insulin resistance in mice [14]. Activation of
hypothalamic NF-kB by central injection of a constitutively active
IKKb lentiviral vector interrupts central leptin and insulin
signaling, while genetic or viral vector mediated suppression of
IKK within the mediobasal hypothalamus protects against obesity
and glucose intolerance in mice [5]. Therefore, compounds that
attenuate the peripheral and hypothalamic inflammation associ-
ated with obesity may prove useful in the management of patients
with obesity and type 2 diabetes.
Some plant-derived triterpenoids are anti-inflammatory and
inhibit the NF-kB signaling pathway [15]. The tetracyclic
triterpenoid ginsenoside Rb1 (Rb1) is the major bioactive
compound extracted from ginseng [16,17]. This compound
inhibits inflammation in in vitro and in vivo models, including
anti-inflammatory effects on aortic smooth muscle exposed to
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TNF-a [18], the colon of colitis mice [19], and brain tissue in an
cerebral ischemia animal model [20]. In high-fat diet-induced
obese rats, Rb1 significantly reduces food intake and body weight
gain [21]. A study by Lin [22] shows that in high-fat diet-induced
obese mice, Rb1 significantly reduces weight gain, blood glucose
and total cholesterol. However, it is unknown whether Rb1 can
improve obesity-associated inflammation and central leptin
resistance.
Materials and Methods
Animal care and treatment
C57Bl/6 male mice (6 weeks old, average body weight of
19.661.4 g) were obtained from the Animal Resources Centre
(Perth, Western Australia) and housed in environmentally
controlled conditions (temperature 22uC, 12 hour light/dark
cycle). All animals were fed a lab chow (LC) diet (5% fat, Vella
Stock Feeds, Doonside, NSW, Australia) ad libitum for one week
and then fed a high-fat (HF) for 16 weeks (The HF diet contained
40% of energy as fat, with the fat content consisting of half lard
and half sunflower oil. The proportion of saturated fat, n-6
polyunsaturated fat, n-3 polyunsaturated fat and monounsaturated
fat were 12%, 16%, 0.4% and 11% respectively. SF11-095,
Specialty Feeds, Western Australia). After 16 weeks of HF diet,
obese mice (average body weight of 44.1862.60 g) were random-
ized into two groups (n = 16 per group) and treated with either
daily intraperitoneal (ip) injections of Rb1 (14 mg/kg, based on a
Rb1 dose (10 mg/kg) described previously in rats [21], and using a
body surface area ratio of 0.14 from rat to mouse [23]) or vehicle
(saline) for 21 days. This study also included a parallel control
group of age-matched mice fed a LC diet. Rb1 purified by high-
performance liquid chromatography (HPLC) to $98% was
purchased from Jilin University in China. During Rb1 treatment
the animal’s food intake and body weight were recorded daily. All
procedures were approved by the Animal Ethics Committee of the
University of Wollongong, NSW, Australia, and complied with the
Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes. The approval ID for this study is AE10/08.
Glucose tolerance test (GTT)
On day 18 of Rb1 treatment, the mice were injected
intraperitoneally with glucose at a dose of 0.5 g/kg after an
overnight fast. Blood samples were taken from the tail vein, and
blood glucose concentration determined using a glucometer
(Freestyle; Abbott Diabetes Care, Alameda, CA) at 0 (fasting),
30, 60 and 120 minutes after glucose injection.
Central leptin sensitivity
Central leptin sensitivity was examined in moderate and
severely obese mice. For moderate obesity, mice were fed a HF
diet for 8 weeks followed by an acute treatment of Rb1 (14 mg/
kg/day, ip) for 2 days. For severe obesity, the mice were fed a HF
diet for 16 weeks and then administered Rb1 (14 mg/kg/day, ip)
for 21 days. The central leptin sensitivity test was performed as
follows. Mice were anesthetized by isoflurane inhalation and
placed in a stereotactic device. An intracerebroventricular (icv)
cannula was implanted into the right lateral brain ventricle
(0.25 mm posterior and 1.0 mm lateral relative to Bregma and
2.5 mm below the surface of the skull) [24]. Five days after
implantation the mice were fasted for 6 hours, and either leptin
(0.1 mg/3 ml) or saline (3 ml) was injected into the lateral ventricle
through the cannula. Food intake and body weight were measured
for 24 hours after the leptin or vehicle injection.
Blood and Tissue collection
Following a further four day interval after examining central
leptin sensitivity, mice were fasted for 6 hours, administered an icv
injection of either leptin (0.1 mg/3 ml) or saline (3 ml) and then
euthanized 1 hour later for tissue collection. Blood, white adipose
tissue, liver and brain tissue were collected. The plasma from mice
receiving saline icv injections was collected after centrifugation at
3000rpm for 15 minutes. Plasma and other tissues were stored at
280uC for further analyses.
Using a standard mouse brain atlas [24], 500 mm frozen brain
sections were cut from Bregma -1.22 mm to -2.72 mm using a
cryostat at a temperature of 218uC. The mediobasal hypothal-
amus was dissected and then collected using a Stoelting Brain
Punch (#57401, 0.5 mm diameter, Wood Dale, Stoelting Co,
USA) in an overlapping pattern over the 3rd ventricle [25].
Determination of plasma leptin, insulin, peptide YY (PYY)
and adiponectin
Plasma leptin, insulin and PYY were measured using the mouse
metabolic magnetic bead panel kit (Merck Millipore, MA), and
adiponectin was assayed with the mouse single plex adiponectin kit
(Merck Millipore).
Histological analysis and morphometry
Epididymal fat was fixed in 10% buffered formaldehyde and
then embedded in paraffin. Tissue sections (5 mm) were cut and
mounted onto polysine slides. The sections were stained with
hematoxylin and eosin and photographed at 1006magnification.
Using the image analysis software Image J 1.46r (http://rsbweb.
nih.gov/ij/download.html), two fields per section and six sections
per fat mass were analyzed to quantify the area and number of
adipocytes.
Western blot analysis
As described in our previous study [26], tissue protein was
extracted using NP-40 Lysis Buffer. The following antibodies were
used: TNF-a (sc-8301), IL-1b (sc-7884), and IL-6 (sc-7920) from
Santa Cruz Biotechnology (Dallas, TX); and p-IkBa (#2859), p-
IKK (#2697), p-STAT3 (#9145), SOCS3 (#2932), and p-
FOXO1 (#9461) from Cell Signaling Technology (Beverly,
MA). Bands corresponding to the proteins of interest were
analyzed using the automatic imaging analysis system Quantity
One (Bio-Rad Laboratories, Hercules, CA). All quantitative
analyses were normalized to b-actin as described in our previous
study [26].
Quantitative real-time PCR (qPCR)
Total mediobasal hypothalamic RNA was extracted using the
Aurum total RNA mini kit (Bio-Rad Laboratories, Hercules, CA)
and reverse-transcribed to first-strand complementary DNA with
the high-capacity cDNA reverse transcription kit (AB Applied
Biosystems, Carlsbad, CA), according to the manufacturer’s
instructions. qPCR was performed in a 20 ml final reaction
volume using SYBR green I master in a Lightcycler 480 (F.
Hoffmann-La Roche Ltd, Basel, Switzerland). Primers used are
listed in Table S1. Amplification was carried out with 45 cycles of
95uC for 10 seconds, 60uC for 30 seconds and 72uC for 30
seconds. The mRNA expression levels for hypothalamic neuro-
peptides were normalized to gamma actin, which served as the
internal control. Experiments were performed in triplicate. The
level of expression for each gene was calculated using the
comparative threshold cycle value (Ct) method, using the formula
22DDCt as described previously [27,28].
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Statistical analysis
Data were analyzed using the SPSS 19 statistical package
(SPSS, Chicago, IL). The two-tailed student’s t-test was used to
compare food intake, adipose tissue histology and weight,
inflammatory markers in epididymal adipose tissue and liver,
and hypothalamic neuropeptides. One-way analysis of variance
(ANOVA) was followed by the post hoc Tukey–Kramer honestly
significant difference (HSD) test was used to analyze final body
weight gain, plasma cytokines, central inflammatory markers, and
central leptin sensitivity. A p,0.05 was regarded as statistically
significant, and p,0.10 were considered a trend. Values are
expressed as mean 6 SEM.
Results
Rb1 treatment lowered food intake and prevented
weight gain and fat deposition in obese mice on a HF
diet
Overall, Rb1 treatment reduced average food intake by 11%
(p,0.05) in HF diet fed mice, and a reduction of food intake was
Figure 1. Effect of chronic administration of Rb1 on food intake, body weight and fat in obese mice fed a HF diet for 16 weeks. Rb1
treatment reduced food intake (A), final body weight gain (C), and visceral and inguinal fat mass (D) (n = 8). Panel B: Body weight of obese mice with
or without Rb1 chronic treatment for 21 days. Panel E: Photographs of epididymal fat tissue, and hematoxylin and eosin staining of epididymal fat
tissue, scale bar: 100 mm. Panel F: Adipocyte area in epididymal fat. Panel G: Frequency distribution of adipocyte surface area in epididymal fat. *p,
0.05 vs. HF control group, #p,0.05 vs. LC lean control.
doi:10.1371/journal.pone.0092618.g001
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observed on days 7, 8, 10, 12, 14, 19 and 20 of Rb1 treatment (all
p,0.05, Fig. 1A) compared with HF control group. Rb1 treatment
significantly reduced body weight gain (Fig. 1C) and visceral and
subcutaneous (inguinal) fat deposition (Fig. 1D and Table 1) in
mice maintained on a HF diet. Rb1 treatment also decreased the
size of adipocytes (an indication of fat storage), with adipocytes
from epididymal visceral fat pads being significantly smaller in
response to Rb1 treatment (Fig. 1E and F). The distribution of
adipocytes by cell surface area showed a higher proportion of
small-sized cells (1,000 mm2) and a lower proportion of larger-sized
cells (5,000–7,000 mm2) in the Rb1-treated group compared to the
HF group (Fig. 1 G).
Table 1. Weight of fat pads in HF diet-induced obese mice with and without ginsenoside Rb1 treatment.
HF Rb1 p-value
Visceral fat (g) 3.7860.17 2.7960.12* ,0.001
Epididymal fat (g) 2.1060.06 1.5060.08* ,0.001
Perirenal fat (g) 0.8560.06 0.5660.04* ,0.001
Mesenteric fat (g) 0.8360.06 0.7360.06 0.236
Inguinal fat (g) 1.5060.08 0.8060.05* ,0.001
HF: high-fat diet–induced obese mice; Rb1: high-fat diet-induced obese mice treated with ginsenoside Rb1. Visceral fat includes epididymal, perirenal and mesenteric.
*p,0.05 vs. HF group. Data are presented as Mean6SEM.
doi:10.1371/journal.pone.0092618.t001
Figure 2. Chronic administration of Rb1 improved plasma profiles and glucose tolerance in obese mice fed a HF diet for 16 weeks.
Rb1 decreased plasma leptin (A) and insulin (B), improved glucose tolerance (C) and AUC (D), and increased adiponectin (E) and PYY (F) in obese mice
(n = 8) fed a HF diet for 16 weeks. *p,0.05 vs. HF control group; #p,0.05 vs. LC diet control group. Data are presented as mean 6 SEM. Area under
the curve for glucose (AUCglucose) was calculated using the trapezoidal rule.
doi:10.1371/journal.pone.0092618.g002
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Rb1 treatment improved blood hormone profiles for
energy balance regulation
HF diet-induced hyperleptinemia was significantly decreased by
Rb1 treatment (Fig. 2A). Plasma insulin was elevated in HF diet-
induced obese mice, but Rb1 did not significantly reverse
hyperinsulinemia in these animals (Fig. 2B). To evaluate the
functional outcome of Rb1 treatment on glucose homeostasis, we
conducted a glucose tolerance test (GTT). Blood glucose was
reduced by Rb1 treatment at the 30 and 60 minute time points of
the GTT (Fig. 2C). The blood glucose area under the curve (AUC)
after glucose injection was reduced in Rb1-treated mice compared
to HF mice without Rb1 treatment (Fig. 2D). Rb1 also increased
plasma adiponectin in HF diet-induced obese mice (Fig. 2E).
Circulating concentrations of the anorexigenic peptide PYY were
significantly increased in the Rb1 treatment group compared with
HF mice (Fig. 2F).
Rb1 treatment decreased inflammation in adipose tissue
and the liver
Given the anti-inflammatory properties of Rb1 in aortic smooth
muscle, colon and brain [18,19,20], we investigated whether Rb1
could reduce low-grade inflammation of adipose and liver tissue in
HF diet-induced obese mice. In the epididymal adipose tissue of
HF mice treated with Rb1, we found significantly reduced
expression of pro-inflammatory cytokines (TNF-a, -44%; IL-6, -
25%; IL-1b, 230%; p,0.05), as well as the inflammatory
signaling molecule p-IKK (244%; p,0.001), compared to HF
control mice (Fig. 3A). In a statistical trend, Rb1 treatment
lowered p-IkBa expression in epididymal adipose tissue (221%;
p=0.06, Fig. 3A). For the liver of HF mice treated with Rb1, the
expression of TNF-a and IL-6 (228% and -28%; p,0.05) was also
significantly reduced compared to HF mice without Rb1
treatment (Fig. 3B). Rb1 treatment lowered SOCS3 expression
in the liver (234%; p=0.08, Fig. 3B) compared to HF control
mice, in a statistical trend. However, no difference was found in
the hepatic expression of IL-1b and p-IKK in HF mice with or
without Rb1 treatment (Fig. 3B).
Rb1 treatment attenuated hypothalamic inflammation
and negative regulators of leptin signaling
A HF diet stimulates pro-inflammatory cytokine mRNA
expression in the hypothalamus of rodents [4], and here we
investigated if Rb1 treatment could attenuate this inflammation.
Using western blot analysis, we confirmed that protein levels of IL-
6, TNF-a and p-IKK increased in the mediobasal hypothalamus
of HF diet-induced obese mice compared with LC diet mice
(Fig. 4A, C and D). The protein levels of SOCS3 and PTP1B,
negative regulators of leptin signaling, also increased in the
mediobasal hypothalamus of HF fed mice (Fig. 4E and F).
Importantly, Rb1 treatment significantly decreased the expression
of IL-6, IL-1b, p-IKK, SOCS3 and PTP1B (-14%, -31%, -15%, -
20% and -14% respectively; p,0.05; Fig. 4) in the hypothalamus
compared with HF control mice.
Rb1 treatment improved central leptin sensitivity and
leptin signaling
To evaluate if Rb1 treatment improved central leptin sensitivity
in conjunction with the inhibition of hypothalamic inflammation,
central leptin sensitivity was examined at two stages in the
development of obesity, at 8 and 16 weeks of HF diet. First, we
demonstrated that icv injection of leptin decreased energy intake (-
31%; p,0.05, Fig. 5A) and body weight gain (p,0.05, Fig. 5D)
compared with saline injection in lean LC fed mice. Second, after
8 weeks of HF diet leptin did not suppress energy intake and body
weight gain in HF control mice (Fig. 5B and E), while acute Rb1
treatment (2 days) restored leptin sensitivity, evidenced by a 41%
reduction in energy intake and a very significant reduction in body
weight gain following leptin icv injection compared to saline icv
injection (p,0.05, Fig. 5B and E). Furthermore, acute Rb1
treatment did not significantly suppress overall food intake and
body weight (Table S2). In severely obese control mice fed a HF
diet for 16 weeks, leptin icv injection did not significantly decrease
energy intake and body weight gain compared with saline (p.
0.05, Fig. 5C and F). With the addition of chronic Rb1 treatment,
icv leptin injections significantly decreased energy intake by -22%
and decreased body weight gain by -251% compared to leptin
injections in obese mice not treated with Rb1 (p,0.05, Fig. 5C
and F). This suggests that the Rb1 chronic treatment increased the
ability of leptin to inhibit energy intake and body weight gain.
To clarify the mechanism by which chronic Rb1 treatment
improved leptin sensitivity, protein expression of the leptin
signaling molecules p-STAT3 and p-FOXO1 was measured in
the mediobasal hypothalamus. Icv injection of leptin increased p-
STAT3 (+55%, p,0.05) in mice fed LC diet, while these responses
were not observed in HF diet-induced obese mice (Fig. 6A). After
Figure 3. Chronic Rb1 treatment reduced peripheral inflammation in obese mice fed a HF diet for 16 weeks. Protein expression of the
pro-inflammatory cytokines TNF-a, IL-6 and IL-1b, as well as the inflammatory signaling molecules p-IKK and p-IkBa in the epididymal fat tissue (A)
and liver (B) in HF-induced obese mice with Rb1 chronic treatment (n = 8). *p,0.05 vs. HF diet control group, +p,0.10 and .0.05 vs. HF control
group. Data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0092618.g003
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Rb1 treatment, the response of leptin signaling molecules was
restored, with a 42% increase in p-STAT3 (p,0.001) following
leptin administration to Rb1-treated HF mice (Fig. 6A). Leptin
also increased phosphorylation of FOXO1 in the mediobasal
hypothalamus of LC diet fed mice, a response that was blunted in
HF mice (Fig. 6B). However, in this case Rb1 treatment did not
restore the leptin-induced increase in p-FOXO1 (Fig. 6B).
Therefore, in the mediobasal hypothalamus, Rb1 acted on the
STAT3 pathways rather than the FOXO1 pathway to restore
leptin signaling.
Rb1 treatment affected the hypothalamic neuropeptides
regulating energy balance
The effect of Rb1 treatment on hypothalamic neuropeptides
expression was examined to investigate the mechanisms by which
this compound suppressed food intake and body weight gain. Rb1
treatment significantly increased anorexigenic pro-opiomelano-
cortin (POMC, +75%; p,0.05) and decreased orexigenic agouti-
related protein (AgRP, -24%; p,0.05) mRNA expression in the
mediobasal hypothalamus of HF mice, but had no effect on
orexigenic neuropeptide Y (NPY) mRNA levels (Table 2).
Discussion
In the current study, Rb1 prevented body weight gain and
reduced fat mass in obese mice fed a HF diet. Rb1 also decreased
average food intake during the course of this study. This is similar
to the study by Xiong and colleagues, which showed that Rb1 has
an anti-obesity effect in rats and its suppression of food intake is
not due to malaise, as attested by a conditioned taste aversion test
[21]. Importantly, our study extends the mechanism of Rb1 in
suppressing food intake. Rb1 treatment increased the anorexigenic
hormone, peptide YY (PYY), in the blood and modulated
Figure 4. Chronic Rb1 treatment reduced hypothalamic inflammation and negative regulators of leptin signaling in obese mice.
Chronic treatment of Rb1 significantly decreased the level of IL-6 (A), IL-1b (B), p-IKK (D), SOCS3 (E) and PTP1B (F) in the mediobasal hypothalamus of
obese mice (n = 6–8) fed a HF diet for 16 weeks without leptin icv injection. Panel C: HF diet significantly increased the protein levels of TNFa in the
mediobasal hypothalamus of mice. *p,0.05 vs HF group, #p,0.05 vs. LC lean control. Data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0092618.g004
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hypothalamic neuropeptides, specifically by increasing anorexi-
genic POMC and decreasing orexigenic AgRP mRNA expression
in HF diet-induced obese mice. Rodent models of HF diet-induced
obesity are characterized by inflammation in both peripheral
tissues and in the hypothalamic regions critical for energy
homeostasis [4,8], which is considered an important mechanism
linking obesity to glucose intolerance, insulin resistance and leptin
resistance. This study has demonstrated that ginsenoside Rb1
treatment provides an anti-obesity-associated inflammatory effect,
with the pronounced reduction of peripheral and hypothalamic
inflammation and improvement of glucose tolerance and central
leptin resistance in HF diet-induced obese mice.
Overnutrition and obesity induce inflammatory responses in
peripheral metabolic tissues, which decreases insulin sensitivity in
target cells (adipocytes and hepatocytes) and contributes to glucose
intolerance and the development of type 2 diabetes [2,8,9,29]. For
example, in obese rodents fed a HF diet macrophages infiltrate the
liver and increase the mRNA expression of the pro-inflammatory
cytokines TNF-a, IL-1b and IL-6 [2,9]. These cytokines activate
NF-kB signaling in hepatocytes, causing hepatic insulin resistance
and glucose intolerance [2,3]. In the current study, Rb1 decreased
the level of pro-inflammatory cytokines (TNF-a, IL-1b and IL-6)
and the inflammatory signaling molecule (p-IKK) in the adipose
tissue and liver, which may have contributed to the improved
glucose tolerance observed in Rb1 treated diet-induced obese
mice. Furthermore, it is well-documented that adiponectin
ameliorates insulin resistance and reduces fatty acid levels in
rodents [30], by decreasing hepatic gluconeogenesis and increas-
ing lipid oxidation in muscle [31,32]. In this study, the increased
adiponectin levels after Rb1 treatment may contribute to the
improved glucose tolerance and reduced fat accumulation that we
observed in obese mice treated with this compound.
Our study demonstrated that chronic treatment with Rb1
suppressed inflammation in the mediobasal hypothalamus of diet-
induced obese mice, as shown by decreased protein expression of
IL-6, IL-1b and p-IKK in this region. In accordance with our
results, another study demonstrated that acute oral administration
of Rb1 significantly reduced IL-6, IL-1b and TNF-a mRNA
expression in mouse brain tissue, and inhibited morphological
activation of microglia following intraperitoneal injections of
lipopolysaccharide endotoxin [33]. Recently, Thaler and col-
leagues demonstrated that mice and rats fed a HF diet had
increased TNF-a and IKK/NFkB mRNA expression in the
hypothalamus [4]. Hypothalamic inflammation is considered a key
pathology of obesity in rodents and humans [34], leading to
central leptin resistance through activation of the negative
regulators of leptin signaling, SOCS and PTP1B [5,12]. Our
results demonstrate that Rb1 decreased the upregulation of
SOCS3 and PTP1B in the hypothalamus of HF diet-induced
obese mice. Therefore, the inhibition of SOCS3 and PTP1B and
attenuation of hypothalamic inflammation, contributes to the
therapeutic effect of Rb1 on central leptin resistance observed in
our mouse model.
The adipocyte-derived hormone leptin promotes negative
energy balance through various signaling pathways (STAT3 and
FOXO1) in the hypothalamus. Constitutive activation of the
inflammatory signaling molecule IKKb in the hypothalamus of
mice impaired STAT3 phosphorylation in response to central
Figure 5. Chronic Rb1 treatment improved central leptin sensitivity in obese mice fed a HF diet for 16 weeks. Energy intake (A–C) and
body weight gain (D–F) for 24 hours after the icv injection of leptin or saline in mice fed a LC diet (n = 7–8), in obese mice fed a HF diet for 8 weeks
with or without acute treatment of Rb1 (14 mg/kg ip daily for 2 days) (n = 7–8), in obese mice fed a HF diet for 16 weeks with or without chronic
treatment of Rb1 (14 mg/kg ip daily for 21 days) (n = 7–8). *p,0.05 vs. (Vehicle + Saline) group; #p,0.05 vs. (Vehicle + leptin) group; and +p,0.05 vs.
(Rb1 + Saline) group. Data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0092618.g005
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leptin administration and induced central leptin resistance [5]. In
our study, leptin induced phosphorylation of STAT3 was restored
after Rb1 treatment in HF mice, suggesting the anti-inflammatory
properties of Rb1 (inhibition of p-IKK in the hypothalamus) may
contribute to this effect. FOXO1, a member of forkhead box
containing protein O superfamily, is highly expressed in the
hypothalamus and contributes to anorexigenic effect of leptin
[35,36]. Leptin signaling through the PI3K/Akt pathway induces
FOXO1 phosphorylation and degradation, decreasing FOXO1
activity in the hypothalamus [35,36]. Phosphorylation of FOXO1
results in its export from the nucleus and allows p-STAT3 to bind
to neuropeptide promoters, stimulating transcription of anorexi-
genic pro-opiomelanocortin (POMC) and inhibiting orexigenic
agouti-related protein (AgRP) expression [37]. In our study,
central leptin injections stimulated FOXO1 phosphorylation in
LC mice, but not in HF mice with central leptin resistance. The
inhibition of leptin-induced FOXO1 phosphorylation in obese
mice with central leptin resistance indicates the impairment of
leptin signaling occurs at the step of FOXO1 phosphorylation or
upstream. In the current study treatment of obese mice with Rb1
restored leptin induced activation of STAT3 phosphorylation, but
not phosphorylation of FOXO1 in the mediobasal hypothalamus.
Therefore, in the hypothalamus, Rb1 acted on the STAT3
signaling pathway rather than the FOXO1 pathway to restore
leptin signaling and sensitivity, although the precise mechanisms
need further examination.
The anti-inflammatory and leptin sensitizing effects of Rb1
treatment could be due to multiple factors. It is likely that reduced
food intake leads to a reduction in fat deposition that in turn
reduces pro-inflammatory cytokines, glucose intolerance and
improves leptin sensitivity. However, a direct effect of Rb1 of
inhibiting inflammation cannot be completely excluded [18,21].
For example, it has been reported in an in vitro study that Rb1
directly inhibited inflammatory responses in rat aortic smooth
muscle cells [18]. Furthermore, in a rat study by Xiong et al, pair-
fed rats with comparable food intake to Rb1 treatment rats did not
show the improved glucose tolerance evident in Rb1 treated
animals, suggesting a direct effect of Rb1 in improving glucose
metabolism [21].
Peptide YY (PYY) is a gut-brain anorexigenic hormone that
promotes negative energy balance by reducing appetite [38].
Peripheral infusion of PYY reduces food intake in rodents [39],
and transgenic mice overexpressing PYY have increased plasma
PYY concentrations, and are protected against diet-induced
obesity [38]. In the present study, the increased plasma PYY in
Rb1 treated HF diet-induced obese mice may have contributed to
the negative energy balance, lower body weight gain and fat
accumulation in these animals. The mechanism by which Rb1
treatment increased circulating PYY levels remains to be
determined. However, PYY is predominantly secreted by intesti-
nal L cells located in the distal gastrointestinal tract [40], and it has
been reported that the PYY levels are decreased in patients with
inflammatory bowel disease [41]. In addition, three days of oral
Rb1 treatment potently inhibited the expression of TNF-a and IL-
1b in the inflamed colon of mice with colitis [19]. Since the colon
of obese mice overexpresses pro-inflammatory cytokines [42], an
anti-inflammatory effect of Rb1 in the gastrointestinal tract may
have increased PYY secretion in obese mice.
The melanocortin system comprises anorexigenic POMC
expressing neurons and orexigenic AgRP expressing neurons in
the arcuate nucleus of the mediobasal hypothalamus [43]. a-
melanocortin-stimulating hormone (a-MSH), a post-translational
product of the POMC gene, binds to the melanocortin receptor 4
(MC4R) and triggers an anorectic signal in the hypothalamus,
while AgRP (an inverse agonist of MC4R) prevents a-MSH
binding to MC4R. Chronic Rb1 treatment significantly increased
POMC and inhibited AgRP mRNA expression in high-fat diet fed
Figure 6. Chronic Rb1 treatment improved central leptin
signaling in obese mice fed a HF diet for 16 weeks. The
phosphorylation of STAT3 (A) and FOXO1 (B) in the mediobasal
hypothalamus 1 hour after the icv injection of leptin or saline in mice
fed a LC diet and obese mice fed a HF diet for 16 weeks with or without
chronic treatment of Rb1 (n = 6–8). *p,0.05 vs. (vehicle + saline) group;
#p,0.05 vs. (vehicle + Leptin) group; +p,0.05 vs. (Rb1 + saline) group.
Data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0092618.g006
Table 2. Relative mRNA expression of neuropeptides in the mediobasal hypothalamus in obese mice fed a HF diet for 16 weeks
with or without Rb1 chronic treatment.
HF Rb1 p-value
POMC 1.0060.14 1.7560.23* 0.034
AgRP 1.0060.05 0.7660.07* 0.045
NPY 1.0060.04 0.9060.09 0.464
HF: high-fat diet-induced obese mice; Rb1: high-fat diet-induced obese mice treated with ginsenoside Rb1. *p,0.05 vs. HF group. Data are presented as Mean 6 SEM.
doi:10.1371/journal.pone.0092618.t002
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mice, implying that Rb1 exerts its anorexigenic action at least
partially by targeting the melanocortin system, the POMC and
AgRP neurons. It is known that these neurons located in the
mediobasal hypothalamus receive and integrate the signaling of
various gut and adipostatic hormones, including PYY, leptin and
insulin. In our study, the effect of Rb1 treatment on the
hypothalamic melanocortin system may be due to increased
plasma PYY, and the improvement of hyperleptinemia and central
leptin sensitivity after Rb1 treatment.
In summary, this study has demonstrated that ginsenoside Rb1
treatment inhibits inflammation in the adipose tissue, liver and
hypothalamus of HF diet induced obese mice. Treatment with
Rb1 resulted in the improvement of glucose tolerance, central
leptin sensitivity and hypothalamic leptin signaling (p-STAT3).
We have also shown that Rb1 treatment increased the circulating
concentrations of the anorexigenic hormone PYY and regulated
melanocortin POMC/AgRP neuropeptides in the mediobasal
hypothalamus, which contribute to negative energy balance.
Ginsenoside Rb1 has the potential for use as an antiobesity
therapeutic agent that functions by modulating obesity-induced
inflammation and improving central leptin sensitivity in HF diet-
induced obesity.
Supporting Information
Table S1 The primers used in qPCR for neuropeptide
mRNA measurement.
(DOCX)
Table S2 Effects of acute Rb1 administration (14 mg/
kg, ip, two days) on body weight and food intake in
obese mice after a high-fat diet feeding for 8 weeks.
(DOCX)
Acknowledgments
The authors wish to thank Ms Linda Cohen for her editorial revision of the
manuscript and Dr. Tracy Maddocks and Hongqin Wang for their
technical support in animal and experimental work.
Author Contributions
Conceived and designed the experiments: YZW YHY XFH. Performed
the experiments: YZW YHY. Analyzed the data: YZW YHY. Contributed
reagents/materials/analysis tools: YZW YHY. Wrote the paper: YZW
YHY AZ MH XFH.
References
1. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and
metabolic disease. The Journal of Clinical Investigation 121: 2111–2117.
2. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, et al. (2005) Local and
systemic insulin resistance resulting from hepatic activation of IKK-[beta] and
NF-[kappa]B. Nat Med 11: 183–190.
3. Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the
immune system and metabolism in disease. Nat Med 18: 363–374.
4. Thaler JP, Yi C-X, Schur EA, Guyenet SJ, Hwang BH, et al. (2012) Obesity is
associated with hypothalamic injury in rodents and humans. The Journal of
Clinical Investigation 122: 153–162.
5. Zhang X, Zhang G, Zhang H, Karin M, Bai H, et al. (2008) Hypothalamic
IKKb/NF-kB and ER stress link overnutrition to energy imbalance and obesity.
Cell 135: 61–73.
6. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell
132: 344–362.
7. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, et al.
(2002) PTP1B regulates leptin signal transduction in vivo. Developmental Cell 2:
489–495.
8. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation
in fat plays a crucial role in the development of obesity-related insulin resistance.
The Journal of Clinical Investigation 112: 1821–1830.
9. Stanton MC, Chen SC, Jackson JV, Rojas-Triana A, Kinsley D, et al. (2011)
Inflammatory Signals shift from adipose to liver during high fat feeding and
influence the development of steatohepatitis in mice. J Inflamm (Lond) 8: 8.
10. Arruda AP, Milanski M, Coope A, Torsoni AS, Ropelle E, et al. (2011) Low-
Grade Hypothalamic Inflammation Leads to Defective Thermogenesis, Insulin
Resistance, and Impaired Insulin Secretion. Endocrinology 152: 1314–1326.
11. Calegari VC, Torsoni AS, Vanzela EC, Arau´jo EP, Morari J, et al. (2011)
Inflammation of the Hypothalamus Leads to Defective Pancreatic Islet Function.
Journal of Biological Chemistry 286: 12870–12880.
12. Milanski M, Arruda AP, Coope A, Ignacio-Souza LM, Nunez CE, et al. (2012)
Inhibition of Hypothalamic Inflammation Reverses Diet-Induced Insulin
Resistance in the Liver. Diabetes 61: 1455–1462.
13. Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC, Prada PcO, Hirabara
SM, et al. (2007) Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents
Diet-Induced Obesity and Insulin Resistance. Diabetes 56: 1986–1998.
14. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z-W, et al. (2001) Reversal of
Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted
Disruption of Ikkb. Science 293: 1673–1677.
15. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J (2008)
Terpenoids: natural inhibitors of NF-kB signaling with anti-inflammatory and
anticancer potential. Cellular and Molecular Life Sciences 65: 2979–2999.
16. Washida D, Kitanaka S (2003) Determination of polyacetylenes and ginseno-
sides in Panax species using high performance liquid chromatography. Chem
Pharm Bull (Tokyo) 51: 1314–1317.
17. Cho J, Park W, Lee S, Ahn W, Lee Y (2004) Ginsenoside-Rb1 from Panax
ginseng C.A. Meyer Activates Estrogen Receptor-{alpha} and -{beta},
Independent of Ligand Binding. J Clin Endocrinol Metab 89: 3510–3515.
18. Li Q-Y, Chen L, Fu W-H, Li Z-D, Wang B, et al. (2011) Ginsenoside Rb1
Inhibits Proliferation and Inflammatory Responses in Rat Aortic Smooth Muscle
Cells. Journal of Agricultural and Food Chemistry 59: 6312–6318.
19. Joh E-H, Lee I-A, Jung I-H, Kim D-H (2011) Ginsenoside Rb1 and its
metabolite compound K inhibit IRAK-1 activation - The key step of
inflammation. Biochemical Pharmacology 82: 278–286.
20. Zhu J, Jiang Y, Wu L, Lu T, Xu G, et al. (2012) Suppression of Local
Inflammation Contributes to the Neuroprotective Effect of Ginsenoside Rb1 in
Rats with Cerebral Ischemia. Neuroscience 202: 342–351.
21. Xiong Y, Shen L, Liu KJ, Tso P, Xiong Y, et al. (2010) Antiobesity and
Antihyperglycemic Effects of Ginsenoside Rb1 in Rats. Diabetes 59: 2505–2512.
22. Lin N, Cai D-L, Jin D, Chen Y, Shi J-J (2013) Ginseng Panaxoside Rb1 Reduces
Body Weight in Diet-Induced Obese Mice. Cell Biochemistry and Biophysics: 1–
6.
23. Paget GE, Barnes JM (1964) CHAPTER 6 - Toxicity Tests. In: Laurence DR,
Bacharach AL, editors. Evaluation of Drug Activities: Academic Press. pp. 135–
166.
24. Paxinos G, Franklin KBJ (2002) The Mouse Brain in Stereotaxic Coordinates,
1st edn., Academic Press, San Diego.
25. White CL, Whittington A, Barnes MJ, Wang Z, Bray GA, et al. (2009) HF diets
increase hypothalamic PTP1B and induce leptin resistance through both leptin-
dependent and -independent mechanisms. American Journal of Physiology -
Endocrinology And Metabolism 296: E291–E299.
26. du Bois TM, Newell KA, Huang X-F (2012) Perinatal phencyclidine treatment
alters neuregulin 1/erbB4 expression and activation in later life. European
Neuropsychopharmacology.
27. Wilusz J, Cheng A, Johnson C, Ford L (2008) A Step-by-Step Procedure to
Analyze the Efficacy of siRNA Using Real-Time PCR. Post-Transcriptional
Gene Regulation: Humana Press. pp. 303–316.
28. Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression Data
Using Real-Time Quantitative PCR and the 22DDCT Method. Methods 25:
402–408.
29. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003)
Obesity is associated with macrophage accumulation in adipose tissue. The
Journal of Clinical Investigation 112: 1796–1808.
30. Lihn AS, Pedersen SB, Richelsen B (2005) Adiponectin: action, regulation and
association to insulin sensitivity. Obesity Reviews 6: 13–21.
31. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous
glucose production is inhibited by the adipose-derived protein Acrp30. The
Journal of Clinical Investigation 108: 1875–1881.
32. Tomas E, Tsao T-S, Saha AK, Murrey HE, Zhang Cc, et al. (2002) Enhanced
muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-
CoA carboxylase inhibition and AMP-activated protein kinase activation.
Proceedings of the National Academy of Sciences 99: 16309–16313.
33. Lee JS, Song JH, Sohn NW, Shin JW (2012) Inhibitory Effects of Ginsenoside
Rb1 on Neuroinflammation Following Systemic Lipopolysaccharide Treatment
in Mice. Phytother Res.
34. Cai D, Liu T (2012) Hypothalamic inflammation: a double-edged sword to
nutritional diseases. Annals of the New York Academy of Sciences 1243: E1–
E39.
35. Kitamura T, Feng Y, Ido Kitamura Y, Chua SC, Xu AW, et al. (2006) Forkhead
protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat
Med 12: 534–540.
Anti-Inflammation of Ginsenoside Rb1 in Obese Mice
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e92618
36. Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, et al.
(2005) Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase
signaling in mediobasal hypothalamic neurons. Cell Metab 2: 411–420.
37. Varela L, Horvath TL (2012) Leptin and insulin pathways in POMC and AgRP
neurons that modulate energy balance and glucose homeostasis. EMBO Rep 13:
1079–1086.
38. Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, et al. (2008) PYY transgenic mice
are protected against diet-induced and genetic obesity. Neuropeptides 42: 19–
30.
39. Chelikani PK, Haver AC, Reidelberger RD (2004) Comparison of the inhibitory
effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. American
Journal of Physiology - Regulatory, Integrative and Comparative Physiology
287: R1064–R1070.
40. Rigamonti AE, Cella SG, Bonomo SM, Mancia G, Grassi G, et al. (2011) Effect
of somatostatin infusion on peptide YY secretion: studies in the acute and
recovery phase of anorexia nervosa and in obesity. European Journal of
Endocrinology 165: 421–427.
41. Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, et al. (2005) Tissue levels
and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-
2, in controls and inflammatory bowel disease: comparison with peptide YY.
Eur J Gastroenterol Hepatol 17: 207–212.
42. Li H, Lelliott C, Hakansson P, Ploj K, Tuneld A, et al. (2008) Intestinal, adipose,
and liver inflammation in diet-induced obese mice. Metabolism 57: 1704–1710.
43. Pritchard LE, Turnbull AV, White A (2002) Pro-opiomelanocortin processing in
the hypothalamus: impact on melanocortin signalling and obesity. J Endocrinol
172: 411–421.
Anti-Inflammation of Ginsenoside Rb1 in Obese Mice
PLOS ONE | www.plosone.org 10 March 2014 | Volume 9 | Issue 3 | e92618
